Abstract
BackgroundGenotypic molecular testing may be very helpful for tuberculosis (TB) drug-resistance surveillance and for treatment guidance in low resource settings.MethodsDescriptive analysis of M. tuberculosis isolates from Beira Central Hospital, Mozambique, during 2014–2015. Genotype MTBDRplus and MTBDRsl were used and patient medical records reviewed.To explore genotypic susceptibility profile of Mycobacterium tuberculosis, to first and second line drugs (SLD) in Beira Mozambique.ResultsOf 155 isolates, 16.1 % (25) were multidrug resistant (MDR), 8.4 % (13) isoniazid-monoresistant and 1.3 % (2) rifampicin-monoresistant. Among MDR-TB, 22.2 % showed primary and 77.8 % represented acquired resistance. The majority of patients with drug resistance had a history of previous TB treatment. Among 125 isolates tested for ethambutol and SLD, 7.2 % (9) were resistant to ethambutol, 4.8 % (6) to fluoroquinolones and 0.8 % (1) to ethambutol and fluoroquinolones. Resistance to injectable SLD was not detected.ConclusionsAs far as we know this is the first report of a genotypic testing used to provide information about SLD resistance in Mozambique, where phenotypic susceptibility testing is usually unavailable. Extensively drug resistant TB was not detected in this isolates from Beira Mozambique.
Highlights
Genotypic molecular testing may be very helpful for tuberculosis (TB) drug-resistance surveillance and for treatment guidance in low resource settings
A total of 155 TB patients confirmed by culture and Genotype MTBDRplus were included
Regarding to the previous use of anti-TB drugs, 4 (16 %) patients with multidrug resistant (MDR)-TB had no previous treatment of TB, while 20 (80 %) patients reported previous TB treatment for more than 30 days
Summary
Genotypic molecular testing may be very helpful for tuberculosis (TB) drug-resistance surveillance and for treatment guidance in low resource settings. Methods: Descriptive analysis of M. tuberculosis isolates from Beira Central Hospital, Mozambique, during 2014–2015. Genotype MTBDRplus and MTBDRsl were used and patient medical records reviewed. To explore genotypic susceptibility profile of Mycobacterium tuberculosis, to first and second line drugs (SLD) in Beira Mozambique. Drug resistant tuberculosis (DR-TB) is a major threat worldwide. In Mozambique, drug resistance is a great challenge for the National Program of TB Control (NPTBC). Genotype MTBDRplus is an LPA recommended by WHO for DR-TB surveillance and diagnostic worldwide [8]. Genotype MTBDRplus evaluates resistance to both isoniazid (H) and rifampicin (R), which is the definition of MDRTB. The test classifies resistance to H according to the mutation detected: high level resistance (mutation in katG gene) and low level resistance
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
